Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era by N. Squillace et al.
© 2018 Squillace et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Drug Design, Development and Therapy 2018:12 3635–3643
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
3635
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/DDDT.S147493
Darunavir–cobicistat–emtricitabine–tenofovir 
alafenamide: safety and efficacy of a protease 
inhibitor in the modern era
Nicola Squillace1 
Giorgio Bozzi2 
elisa Colella1 
Andrea Gori2 
Alessandra Bandera1
1infectious Diseases Unit, Azienda 
Socio Sanitaria Territoriale di Monza, 
San Gerardo Hospital, University 
of Milano-Bicocca, Monza, italy; 
2infectious Disease Unit, Department 
of internal Medicine, Fondazione 
iRCCS Ca’Granda, Ospedale 
Maggiore Policlinico, Department of 
Pathophysiology and Transplantation, 
University of Milano, Milan, italy
Abstract: A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), 
emtricitabine (2′,3′-dideoxy-5-fluoro-3′-thiacytidine [FTC]), and tenofovir alafenamide (Taf) 
has been recently approved by the European Medicines Agency for the treatment of HIV infec-
tion, and is the first ever protease-inhibitor-based single-tablet regimen. This article provides a 
detailed description of its pharmacokinetic, efficacy, and safety profile. The pharmacokinetics 
of single compounds were analyzed, with a special focus on contrasts between Drv/Cobi and 
Drv/ritonavir (Rtv). When comparing Cobi and Rtv, multiple interactions must be taken into 
account: in comparison to Rtv, Cobi is a more selective CYP3A4 inhibitor and has no clinical 
effect on other isoenzymes inhibited by Rtv (eg, 2C8 and 2C9). Moreover, unlike Cobi, Rtv 
shows in vivo induction activity on some CYP isoenzymes (eg, 1A2, 2C19, 2C8, 2C9, and 
2B6), glucuronyltransferases (eg, UGT1A4), and Pgp. Drv-Cobi-FTC-Taf has recently been 
demonstrated to be of equal efficacy to Drv-Rtv and other protease inhibitors in both expe-
rienced (EMERALD study) and naïve (AMBER study) patients. Moreover, kidney and bone 
safety profiles have been shown to be good, as has central nervous system tolerance. Total 
cholesterol:low-density-lipoprotein cholesterol and total cholesterol:high-density-lipoprotein 
cholesterol ratios are generally high in Drv-Cobi-FTC-Taf vs Rtv-Drv-FTC + tenofovir diso-
proxil fumarate. An unlikely role of Drv in influencing cardiovascular risk in HIV infection has 
also been reported. Kidney safety profile is influenced by Cobi, with an increase in creatinine 
plasma concentration of 0.05–0.1 mg/dL and a parallel glomerular filtration-rate reduction of 
10 mL/min within the first 4 weeks after Cobi introduction, which remains stable during treat-
ment. Bone and central nervous system safety profiles were found to be good in randomized 
clinical trials of both experienced and naïve patients. The efficacy and safety of Drv/Cobi/FTC/
Taf are comparable to other drug regimens recommended for HIV treatment.
Keywords: protease inhibitors, darunavir/cobicistat, emtricitabine/tenofovir alafenamide, 
HIV
Introduction
The use of protease inhibitors (PIs) as a component of combination antiretroviral 
therapy (ART) has radically improved the prognosis of HIV infection, leading to sig-
nificant and durable control with immunorestoration and increasing life expectancy.1 
In the first years of introduction, however, high efficacy was counterbalanced by a 
large burden of adverse events, such as lipodystrophy, dyslipidemia, and insulin 
resistance.2 Atazanavir (Atv) was the first PI prescribed once daily, followed by 
darunavir (Drv) which proved to be as efficacious as other PIs, but with a better 
lipid and metabolic profile and a lower rate of lipodystrophy.3,4 Recently developed, 
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tenofovir alafenamide (Taf) has been shown to be equally 
effective and have lower toxicity than tenofovir disoproxil 
fumarate (TDF).5–7
The introduction of single-tablet regimens (STRs) has 
changed the scenario in the management of HIV infec-
tion, significantly increasing adherence and quality of life 
of people living with HIV.8 Until last year, STRs were 
available only for nonnucleoside reverse-transcriptase 
inhibitors and integrase inhibitors. The newly approved 
one-pill combination of Drv, cobicistat (Cobi), emtricit-
abine (2′,3′-dideoxy-5-fluoro-3′-thiacytidine [FTC]), and 
tenofovir alafenamide (Taf), being PI-based, thus represents 
a novelty in HIV therapy. The aim of this review was to 
evaluate the pharmacokinetics, efficacy, and safety of Drv-
Cobi-FTC-Taf.
Drv-Cobi-FTC-Taf pharmacokinetics
Taf
After intestinal absorption, Taf enters hepatocytes by pas-
sive diffusion, facilitated by organic anion-transporting 
polypeptides 1B1 and 1B3. It is then metabolized by car-
boxylesterase 1 to form tenofovir (Tfv), which phospho-
rylates to Tfv diphosphate, its active metabolite.9,10 Taf is 
more stable than TDF in plasma: in vitro, the plasma half-
life of Taf is 30–90 minutes compared to 0.4 minutes for 
TDF, allowing for efficient uptake by hepatocytes.11,12 Tfv 
is eliminated through the kidneys by both active proximal 
tubule secretion and passive glomerular filtration: lower-
ing the administered Tfv equivalents decreases kidney 
exposure. Incubation of primary human hepatocytes with 
Taf in vitro shows high intracellular concentrations of Tfv 
diphosphate, approximately five and 120 times higher than 
concentrations observed with TDF and Tfv, respectively. Tfv 
diphosphate has been demonstrated to be a potent inhibitor 
of HBV replication.10,13 In severely hepatically impaired 
(Child–Pugh C) patients uninfected with HIV treated with 
Taf 25 mg, Tfv exposure has been reported to be only 
modestly lower compared to healthy controls with normal 
hepatic function.14 In patients with severe renal impairment 
receiving treatment with Taf 25 mg, plasma levels of Tfv 
were lower than those historically seen in pharmacokinetic 
studies using TDF in antiretroviral regimens for HIV-infected 
patients with normal renal function, albeit higher than in 
matched healthy subjects.14 A study on the effect of food on 
Taf pharmacokinetics showed that Taf exposure decreased 
in fasting conditions.15 However, no significant trend in 
exposure response/safety regarding Taf exposure was found 
in fasting or fed conditions.11
Drv-Cobi
Like most PIs, Drv is metabolized extensively through 
CYP3A4 in the liver and the gut.16 Once-daily administration 
and lower doses can thus be achieved by coadministering a 
pharmacokinetic enhancer. Until recently, low-dose ritonavir 
(Rtv; 100 mg once or twice daily), a strong CYP3A4 and Pgp 
inhibitor, was the staple pharmacokinetic booster available.17 
However, this enhancement is not limited to antiretroviral 
drugs, but affects other drugs metabolized through CYP, 
with risk of side effects. In order to overcome this issue, 
a new antiretroviral drug booster, Cobi, was developed from 
the Rtv molecule. Despite being similar to Rtv in many 
aspects, Cobi inhibits CYP isoenzymes more selectively 
and does not cause induction effects on glucuronidation or 
CYP.18 Furthermore, Cobi has high aqueous solubility and 
can be readily coformulated with other agents. It is currently 
used in fixed-dose combinations (FDCs) to enhance plasma 
concentrations of elvitegravir, Atv, and Drv. Importantly, 
while Rtv has activity against HIV, possibly leading to the 
development of drug-resistance mutations to PIs in cases 
of suboptimal regimens, Cobi is devoid of intrinsic activity 
against HIV replication.19,20 Recently, Drv 800 mg and Cobi 
150 mg have become available in an FDC (Rezolsta; Johnson 
and Johnson, New Brunswick, NJ, USA).
Drv achieves peak plasma concentration (C
max
) in 
3–4.5 hours after oral administration of Drv-Cobi 800/150 mg. 
Administration with food significantly increases Drv absorp-
tion, raising C
max
 more than double and Drv area under the 
curve (AUC) up to 1.7-fold (Cobi pharmacokinetics are 
unaffected).21,22 Cobi binds to plasma proteins at up to 98%, and 
is mostly eliminated through feces (86%).23 In a study involv-
ing healthy volunteers, apparent volume of distribution was 
269 and 158 L for Cobi 100 and 200 mg/day, respectively.24 
Cobi has a short median plasma half-life (3–4 hours).23 In a 
phase 1, open-label, randomized clinical trial comparing the 
bioavailability of two distinct Drv-Cobi 800/150 mg once-
daily coformulations and Drv-Rtv 800/100 mg once daily, 
Drv AUC 24 hours and C
max
 with either enhancer were found 
to be comparable.25 In a phase IIIB study of 60 HIV-infected 
patients, the pharmacokinetic profile of Drv was analyzed by 
administering Drv 800 mg and Cobi 150 mg (as single agents) 
with any nucleoside reverse-transcriptase-inhibitor backbone 
(mostly TDF-based).26 Mean Drv AUC, C
max
, and C
trough
 values 
± SD were 81,646±26,322 ng⋅h/mL, 7,663±1,920 ng/mL, 
and 1,311±969 ng/mL, respectively, comparable to results 
observed in healthy volunteers.20,25,27,28 Geometric mean val-
ues 24 hours after the observed dose for Cobi-boosted Drv 
were reported to be 43 ng/mL in saliva and 11,878 ng/mL in 
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urine. Concentration decay in saliva/urine was found to mirror 
plasma concentrations.29 Cobi and Rtv produce comparatively 
effective Drv concentrations in cerebrospinal fluid.30
Drug–drug interactions with Drv-Cobi
As mentioned, Cobi functions primarily as a pharmacokinetic 
enhancer by means of CYP3A4 inhibition. However, other 
enzymes and transporters are weakly inhibited by Cobi (see 
Figure 1).20,21,27 In comparison to Rtv, Cobi is a more selective 
CYP3A4 inhibitor, as it is devoid of effects on other isoen-
zymes. It also lacks the induction activity of Rtv on several 
enzymes and transporters, including CYP isoenzymes, Pgp, 
and glucuronyltransferases.15,31,32
Table 1 summarizes the main differences between Rtv 
and Cobi.31 Coadministration of Cobi and Pgp substrates 
(ie, digoxin), may increase the latter drug’s plasma levels, 
possibly leading to adverse events.33 Conversely, coadmin-
istered drugs that inhibit/induce CYP3A4 will affect Cobi 
plasma concentrations. Cobi concentrations are increased 
by coadministration with other inhibitors, increasing the 
risk of toxicity, while in contrast CYP3A inducers may 
lower Cobi concentrations, possibly leading to the emer-
gence of drug-resistance mutations and virological failure. 
Importantly, as some nonnucleoside reverse-transcriptase 
inhibitors, namely etravirine, efavirenz, or nevirapine (but 
not rilpivirine), can be strong inducers, their coadministra-
tion with Cobi is contraindicated.34 Relevant discrepancies 
between Cobi and Rtv have been reported for interactions 
with rifabutin35,36 and warfarin.37 There are no available data 
on the usage of Cobi as a pharmacokinetic enhancer for PIs 
other than atazanavir or Drv. Furthermore, the Drv-Cobi 
combination is not potent enough to boost the activity of 
other coadministered drugs, such as elvitegravir, meaning 
that coadministration might pose a risk of suboptimal plasma 
levels, possibly leading to virological failure.35,38
Drv-Cobi-FTC-Taf fixed-dose 
combination pharmacokinetics 
phase I studies
The phase I trial NCT02578550 confirmed the bioequivalence 
of FDC Drv-Cobi-FTC-Taf relative to the separate agents 
(Drv 800 mg tablet formulation and FTC-Taf 200/10 mg 
FDC) in the presence of 150 mg Cobi under fed conditions 
in healthy participants (see Table 2). The impact of food on 
the bioavailability of coformulated Drv-Cobi-FTC-Taf was 
tested in the phase I trial NCT02475135.39 Food effects with 
Drv were observed only after administration of Drv-Cobi-
FTC-Taf. It is thus recommended that Drv-Cobi-FTC-Taf 
be taken with food, which is also the recommendation in the 
ongoing phase III trials.40
Efficacy: phase II and III studies
In an exploratory phase II trial (ClinicalTrials.gov 
NCT01565850; GS-US-299-0102)41 in 153 treatment-naïve 
adults with estimated glomerular filtration rate (GFR) $70 
mL/min, the virological efficacy of the Drv-Cobi-FTC-Taf 
regimen was compared to a regimen containing Drv and 
Cobi combined with FTC and TDF with 2:1 double-blinded 
randomization (see Table 2).42 At week 24, viral suppression 
(HIV1 RNA ,50 copies/mL) rates were similar (74.8% for 
Taf vs 74.0% for TDF; US Food and Drug Administration 
[FDA] snapshot analysis, primary end point, with a 12% 
margin for noninferiority). At week 48, however, rates 
were 76.7% for the Taf-containing STR vs 84.0% for the 
TDF-containing regimen. This difference appeared to be 
driven by a higher rate of discontinuations in the Taf (6.8%) 
vs TDF arm (2%). On the other hand, significant renal and 
bone safety improvements were observed in the Taf arm. 
Of note, no resistance to any compound was observed. 
A single-tablet, once-daily regimen of Drv 800 mg–Cobi 
150 mg–FTC 200 mg–Taf 10 mg is currently under inves-
tigation in two international, randomized, phase III studies: 
EMERALD (ClinicalTrials.gov NCT02269917) and 
AMBER (NCT02431247; see Table 2).43,44
EMERALD was a randomized, active-controlled, open-la-
bel, international, multicenter trial carried out in nine countries 
in North America and Europe that began on March 30, 2015.45 
The aim of the study was to evaluate safety and efficacy of 
single-tablet Drv-Cobi-FTC-Taf as a potential switch option 
&<3$/LYHUJXW
&2%,
0$7(.LGQH\
%&53*XW
2$73%/LYHU3JS/LYHUJXW
&<3'/LYHU
Figure 1 Activity of cobicistat (Cobi).
Abbreviations: BRCP, breast cancer resistance protein; COBi, cobicistat; CYP2D6, 
Cytochrome P450 2D6; CYP3A4, Cytochrome P450 3A4; MATe-1, Multidrug and 
toxin extrusion protein-1; OATP, organic-anion-transporting polypeptide; P-gp, 
P-glycoprotein.
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for the treatment of HIV1 infection in adults with viral sup-
pression. Treatment-experienced and virologically suppressed 
(viral load ,50 copies/mL for $2 months) HIV1-infected 
adults were eligible. One viral load of 50–200 copies/mL was 
allowed within 12 months before screening, and patients with 
a history of virological failure on regimens other than Drv-
containing were allowed. Patients were randomly assigned 
(2:1) to switch to the open-label study regimen or continue the 
control regimen. The primary outcome was the proportion of 
participants with virological rebound (either confirmation of 
viral load $50 copies/mL or premature discontinuation, with 
last viral load $50 copies/mL). Noninferiority was tested 
(4% margin) vs the control regimen in the intention-to-treat 
population. Of 1,141 total patients (763 and 378 in the study 
and control groups, respectively), 58% had previously received 
five or more antiretrovirals, including screening drugs, and 
15% had experienced previous non-Drv virological failure. 
The study regimen was found to be noninferior for virological 
rebound (2.5% patients vs 2.1% in the study and control groups, 
respectively; difference 0.4%, 95% CI–1.5–2.2; P,0.0001). 
No accumulation of drug resistance was observed. The propor-
tion of adverse event-related discontinuations (1% in the study 
group vs 1% in the control group) and grade 3–4 adverse events 
(7% vs 8%, respectively) was similar between groups. A small, 
statistically significant (0.2±1.1 vs 0.1±1.1, P=0.010) difference 
between groups in change from baseline in total:high-density 
lipoprotein (HDL) cholesterol ratio was reported; however, 
this difference was not deemed to be clinically relevant. Only 
one serious adverse event (a case of pancreatitis) was reported 
to be possibly related to the study regimen.
The purpose of the AMBER study46 is to demonstrate 
efficacy noninferiority of a Drv-Cobi-FTC-Taf FDC tablet 
vs Drv-Cobi FDC coadministered with FTC-TDF in 725 
HIV1-infected, ART-naïve adult participants in the context 
of a multicenter, randomized, double-blind, active-controlled 
study beginning July 6, 2015. The primary outcome of 
the study is the percentage of participants obtaining HIV 
RNA ,50 copies/mL defined by the FDA snapshot approach 
(time frame: week 48). Unpublished results at week 48 
showed the FDC to be noninferior to the combination of Drv-
Cobi and Taf-FTC in terms of efficacy (with 91.4% vs 88.4% 
patients achieving virological suppression, respectively).46 
Interestingly, neither arm developed Drv, primary PI or TDF-
Taf Resistance Associated Mutations (RAMs). One patient 
in the Drv-Cobi-Ftc-Taf arm, however, developed M184I/V, 
which confers high-level in vitro resistance to lamivudine 
and FTC while increasing susceptibility to TDF.47 Few seri-
ous adverse events or adverse event-related discontinuations 
were reported: diarrhea and rash were the most commonly 
reported adverse events in both arms.
Table 1 Principal differences in drug interactions between booster dosing of ritonavir (Rtv) and cobicistat (Cobi)
Drug Rtv Cobi
etravirine (etv) No interactions ↓↓↓etv*
Nevirapine (Nev) No interactions ↓↓↓Nev*
efavirenz (efv) ↑efv, ↑Rtv ↓↓↓Cobi*
Rifabutin ↑Rifabutin ↓↓Cobi
Olanzapine ↓Olanzapine No interactions
Sertraline ↓Sertraline ↑Sertraline
Carbamazepine ↑Carbamazepine ↓↓↓Cobi*
Acenocumarol ↑Acenocumarol No interactions
Propofol ↓Propofol No interactions
Lamotrigine ↓Lamotrigine No interactions
valproate ↓valproate No interactions
Gliclazide ↓Gliclazide No interactions
Metformin No interactions ↑Metformin exposure
Mycophenolic acid variable interactions: ↓↑ No interactions
Gemfibrozil ↓Gemfibrozil No interactions
Pitavastatin No interactions ↑Pitavastatin
Notes: ↑, Potential increase in drug exposure; ↑↑, moderate increase in drug exposure; ↑↑↑, significant increase in drug exposure; ↓, potential decrease in drug exposure; 
↓↓, moderate decrease in drug exposure; ↓↓↓, significant decrease in drug exposure. Reference www.hiv-druginteractions.org, *contraindicated.
Abbreviations: etv, etravirine; Nev, nevirapine; efv, efavirenz; Rtv, ritonavir; Cobi, cobicistat.
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Drv-Cobi safety
Available data regarding Drv-Cobi 800/150 mg once-daily 
combination safety and tolerability reveal mild adverse 
events, due to gastrointestinal disturbances (diarrhea, nausea, 
flatulence) and rash or other skin reaction.26 During the Drv 
clinical development program, severe skin reactions were 
occasionally described, while in the postmarketing phase 
grade acute skin reactions were at times reported. Cau-
tion must be taken with patients with past hypersensitivity 
reactions during sulfonamide use, because of the reported 
higher probability of developing the same adverse event 
with Drv.21,26
The updated unpublished AMBER study reported the 
tolerability profile of Drv-Cobi-FTC-Taf at 48 weeks to be 
good (randomized double-blind phase: Drv-Cobi-FTC-Taf 
matched with TDF-FTC + Drv-Cobi placebo vs TDF-FTC + 
Drv-Cobi matched with Drv-Cobi-FTC-Taf placebo), with 
no discontinuations due to renal, bone, or central nervous 
system adverse events.46 Cobi inhibits human renal transport-
ers (see Figure 1).48 Because of those inhibitions in urinary 
creatinine excretion, an increase in creatinine plasma concen-
tration of 0.05–0.1 mg/dL and a parallel GFR reduction of 
10 mL/min are expected within the first 4 weeks after Cobi 
introduction, with stabilization occurring during treatment 
and resolving with Cobi discontinuation, with no effect on 
actual clearance.49,50 Drv-Cobi was also studied in patients 
with no severe renal impairment in the GS-US-236-118 
Study, which showed stable estimated GFR (eGFR; measured 
by cystatin C) at week 96.51 The metabolic profile of Drv-
Cobi-FTC-Taf observed at 48 weeks in the EMERALD45 
and AMBER studies revealed significant increases in total 
cholesterol, low-density lipoprotein (LDL) cholesterol, and 
total cholesterol:HDL-cholesterol ratio, with no significant 
increase in lipid-lowering therapy prescription in the study 
arm. These results were partially attributable to the process 
of comparing Taf vs TDF in both studies, given the former’s 
relative lack of lipid-lowering effect.52
The cardiovascular safety of Drv has also been studied 
through postmarketing analysis comparing its effects on 
endothelial cell function with those of other PIs. Drv has 
been shown to have minimal or no effect on induction of 
endothelial oxidative stress and inflammation (ie, phospho-
rylation of p65/RelA-NFκB) compared to atazanavir and 
lopinavir.53 Secretion of soluble ICAM or VCAM has been 
shown not to be significantly altered by Drv or Drv-Rtv.53 
Similar results were observed regarding senescence mark-
ers, such as senescence-associated β-galactosidase activa-
tion and overexpression of phospho-p53, p16INK4, p21WAF1, 
and prelamin A.53 Instead, interestingly, an intermediate 
effect of Atv-Rtv and a strong effect of lopinavir–Rtv on 
all these inflammation and endothelial activation markers 
has been demonstrated.53 Evaluation of cardiovascular risk 
associated with Drv-Rtv has produced conflicting results, 
both in randomized clinical trials and observational studies. 
In the MONARCH trial,54 no effect on endothelial func-
tion (measured by flow-mediated dilation) was observed 
when switching from a standard ART regimen to Drv/Rtv 
monotherapy or to Drv-Rtv + a combination of nucleoside 
reverse-transcriptase inhibitors. Data from the DAD study 
showed a markedly increased incidence of cardiovascular 
events associated with Drv-Rtv in a cohort of 35,711 patients 
with a median follow-up of 7 years.55
Furthermore, recent unpublished data based on CVD 
events in postmarketing pharmacovigilance databases con-
ducted on 5,721 patients enrolled in 19 Janssen-sponsored 
clinical trials did not indicate an increased risk of CVD 
events with Drv-Rtv use in treatment duration up to 6 years, 
although a significantly higher rate of cardiovascular events 
in patients receiving Drv 600–Rtv 100 mg twice daily vs 
Drv 800–Rtv 100 mg once daily was observed.56 Data on 
cardiovascular events in patients on Drv-Cobi-FTC-Taf 
are scarce: neither the EMERALD nor the AMBER study 
reported a significant incidence of such adverse events.45,46 
Further studies are needed to evaluate the long term safety 
of this compound and to ascertain the unlikely association 
of Drv with cardiovascular events. Few studies have directly 
addressed Drv and Cobi bone toxicity/safety. It is possible to 
approximate Drv and Cobi bone safety profiles by examining 
the results of the NEAT trial, which compared Drv-Rtv + 
raltegravir to Drv-Rtv + TDF-FTC at 48 weeks: differences in 
bone-mineral density (BMD) changes were more pronounced 
in the TDF-containing regimen, where significant increases 
in serum markers of bone turnover were observed.57,58
A recent study evaluated impact on bone by Drv-Cobi-
FTC and TDF/Taf. At week 48, a better BMD profile was 
reported in the Taf group: compared to the TDF group, more 
patients had an increase in BMD at the hip or spine (5% 
and 11% for Taf vs 0 and 2% for TDF, respectively), and 
fewer patients had decreased BMD at the hip or spine (18% 
and 33% for Taf vs 62% and 55% for TDF, respectively). 
Interestingly, an AIDS Clinical Trials Group (ACTG) 
A5257 substudy found similar BMD loss among regimens 
with different PIs, such as Atv-Rtv and Drv-Rtv, but lower 
in patients receiving raltegravir. Of note, all subjects in the 
two PI arms received TDF, and because Rtv coadministra-
tion increases Tfv concentrations by approximately 30%, 
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some of the effects described might have to be related to 
enhanced TDF exposition, rather than to a direct effect 
of PIs on bone.59,60 Conversely, data from ACTG A5224s 
showed a similar PI effect (Atv-Rtv) with either TDF-FTC 
or abacavir–lamivudine.61
The recently published EMERALD study had a bone-
investigation substudy investigating the efficacy and safety 
of switching to a single-tablet Drv-Cobi-FTC-Taf regimen 
vs continuing a regimen of boosted PI plus TDF-FTC. The 
substudy reported a BMD increase at the hip, lumbar spine, 
and femoral neck at week 48 in the study group (P,0.0001 
for ANCOVA within-treatment comparison at hip and lumbar 
spine and P=0.029 for femoral neck). Conversely, in the con-
trol group, at week 48 hip BMD was stable, whereas lumbar 
spine and femoral neck BMD had decreased (P=0.78 for 
ANCOVA within-treatment comparison at the hip, P=0.98 
for lumbar spine, and P=0.34 for femoral neck). Moreover, 
ANCOVA comparison among treatments showed P,0.0001 
for the hip and lumbar spine and P=0.004 for the femoral 
neck.45 In the AMBER study,46 better bone profiles were 
observed in patients on Drv-Cobi-FTC-Taf vs Drv-Cobi-
FTC-TDF, with a significantly minor decrease in spine and 
neck BMD. All these observations point to a good safety 
profile of Drv and Cobi in terms of bone metabolism. Liver 
toxicity was reported in 0.5% of patients on treatment with 
Drv. Due to its pharmacokinetic characteristics (Drv and Cobi 
are metabolized mainly by the liver) and in consideration of 
data on hepatic safety, Drv is contraindicated in patients with 
severe hepatic impairment and severe liver insufficiency.62 
Central nervous system adverse events have rarely been 
reported (,1%) in randomized clinical trials involving 
experienced45 and naïve patients.46
Taf-FTC safety
Many clinical trials have documented the safety and effi-
cacy of Taf in treatment-naïve and experienced adults in 
combination with other FDCs.5,6,63 These studies observed 
improvements in median changes of estimated eGFR at week 
48 in the switch groups. Median urine protein at week 48 
decreased more in the switch groups compared to the control 
group. No cases of proximal renal tubulopathy or Fanconi 
syndrome were observed. Fasting lipid values increased 
from baseline in the switch groups, with no statistically 
significant changes in total cholesterol:HDL ratio.5,6,63 BMD 
measured by dual-energy X-ray absorptiometry increased in 
the switch groups and remained stable or decreased in the 
control groups, showing a good bone safety profile for Taf 
compared to TDF.
An interesting meta-analysis64 can summarize the afore-
mentioned observations. It identified not only significantly 
smaller reductions in eGFR-Crocroft-Gault (CG), smaller 
changes in Retinol Binding Protein (RBP):creatinine (Cr) 
and urine β
2
 microglobulin:Cr ratio, and less reduction in 
spine and hip BMD in treatment-naïve patients but also 
significant efficacy advantages of improved renal function 
and BMD. These included significant decreases in urine 
albumin:Cr, urine protein:Cr, urine RBP:Cr, and urine β
2
 
microglobulin:Cr ratios and increases in hip and spine BMD 
by 1.47% and 1.56%, respectively, compared with continued 
TDF regimens. Moreover, in this analysis a higher viral sup-
pression rate in patients switching to Taf was observed.64 
This observation was recently reinforced in a randomized, 
active-controlled, multicenter, open-label trial that confirmed 
the superiority of Taf vs TDF in virological efficacy.7 Finally, 
a recent study remarked that since coadministration with 
Cobi results in significantly higher Tfv concentrations and 
higher TDF discontinuation compared to other antiretroviral 
regimens, registration trials of Taf65 may have been prone to 
bias when evaluating safety comparisons with Taf.
Conclusion
Drv-Cobi-FTC-Taf is a drug regimen with demonstrated 
efficacy in HIV infection. The safety and tolerability of 
this combination is comparable to other STRs available at 
this time. PIs maintain a role in treatment of HIV infection, 
especially in naïve patients when an ART regimen needs 
to be initiated as soon as possible and resistance tests and 
HLA-B5701 are not available, as well as in experienced 
patients, when virological failure to nonnucleoside reverse-
transcriptase inhibitors or integrase strand-transfer inhibitor 
is demonstrated and an STR with a high genetic barrier and 
low-toxicity profile is required.
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